( December 21, 2015, 12:00 PM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on Dec. 4 said a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors has resulted in new label warnings about the risk of excess acid in the blood and of serious urinary tract infections, both of which can result in hospitalization....